Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blinded, Controlled with GARDASIL (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old men

Next Previous
Trial Profile

A Randomized, Double-Blinded, Controlled with GARDASIL (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old men

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs V 503 (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
  • Indications Cervical cancer; Condylomata acuminata; Genital warts; Human papillomavirus infections; Vulvovaginal cancer
  • Focus Pharmacodynamics; Registrational
  • Sponsors Merck Sharp & Dohme; Sanofi Pasteur

Most Recent Events

  • 25 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 29 May 2015 Planned End Date changed from 1 Feb 2015 to 1 Jul 2015, according to ClinicalTrials.gov record.
  • 29 May 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Jul 2015, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top